News | February 24, 2009

Study Finds Decrease in Percentage of Uninterpretable, Technically Difficult Studies with Contrast Echocardiography

February 24, 2009 - Lantheus Medical Imaging Inc. today said a paper published online in the February 2009 issue of the Journal of the American College of Cardiology reinforces the clinical use and impact of its echocardiography contrast agent DEFINITY Vial For (Perflutren Lipid Microsphere) Injectable Suspension in hospitalized and critically ill cardiac patients.

New data from a prospective, single center, cohort study of more than 600 patients finds the use of contrast echocardiography with DEFINITY in technically difficult cases improves endocardial visualization and significantly impacts cardiac diagnosis, resource utilization and patient management decisions. The study authors include William A. Zoghbi, M.D., FACC, and his colleagues at Cardiovascular Imaging Institute, The Methodist DeBakey Heart and Vascular Center in Houston, TX.

The prospective study was designed to evaluate the impact of echocardiographic contrast utilization on patient diagnosis and management. While contrast echocardiography (CE) has improved left ventricular opacification and delineation of endocardial borders, its impact on physician decision-making has not been evaluated in a large study.

The study shows the use of DEFINITY helps better define left ventricular opacification and endocardial border delineation to help physicians significantly improve left ventricular functional assessments and the detection of left ventricular thrombus, the company said. In doing so, other more costly tests were avoided and drug therapies were better tuned to patient needs.

A total of 632 consecutive patients (545 hospitalized inpatients and 87 outpatients) with technically difficult studies who underwent a rest echocardiogram and received DEFINITY for endocardial enhancement from June to October 2007 were enrolled in the study. A technically difficult study was defined as a study in which >2 myocardial segments were not visualized at baseline from any imaging window. Quality of the studies, number of left ventricular (LV) segments visualized, estimated left ventricular ejection fraction (LVEF), the presence, absence or suspicion of apical thrombus, and management decisions were compared before and after contrast.

The study found the percent of uninterpretable studies decreased from 11.7% to 0.3% and the number of technically difficult studies decreased from 86.7% to 9.8% (p A significant impact of CE on management was observed. In particular, additional diagnostic procedures were avoided in 32.8 percent of patients and drug management was altered in 10.4 percent, with a total impact (procedures avoided, change in drugs, or both) observed in 35.6 percent of patients. The impact of contrast increased with worsening quality of baseline non-enhanced study, the highest being in intensive care units. Lantheus did not provide funding for the study.

Online copies of the article can be found at Journal of the American College of Cardiology: “Impact of Contrast Echocardiography on Evaluation of Ventricular Function and Clinical Management in a Large Prospective Cohort,” by Mustafa Kurt, M.D., et al, at http://content.onlinejacc.org/cgi/content/full/j.jacc.2009.01.005v1

For more information: www.lantheus.com

Related Content

News | Contrast Media | November 14, 2018
Voyageur Minerals Ltd. signed a joint venture agreement with Chief Medical Supply Ltd (CM) of Calgary, Alberta to...
Fujifilm SonoSite Launches New Point-of-Care Ultrasound Educational Resources
News | Ultrasound Imaging | November 01, 2018
Fujifilm SonoSite Inc. announced the launch of its redesigned SonoSite Institute, a comprehensive online educational...
Vygon and Sonoscanner Partnering on New Ultrasound System for Catheter Placement Guidance
News | Cardiovascular Ultrasound | October 31, 2018
Vygon, an international group specialized in single-use medical devices, and French company Sonoscanner announced the...
Cardiac Ultrasound Software Streamlines Fetal Heart Exams
Feature | Cardiovascular Ultrasound | October 30, 2018
A new tool called fetalHQ on GE Healthcare’s Voluson ultrasound systems is the first tool to simultaneously examine the...
Hitachi Supports ASE Foundation Cardiovascular Outreach Mission in West Virginia
News | Cardiovascular Ultrasound | October 29, 2018
Hitachi Healthcare Americas participated in the cardiovascular screening and diagnostic triage event that took place...
Osprey Medical and GE Healthcare Launch Acute Kidney Injury Educational Program
News | Angiography | September 25, 2018
September 21, 2018 — Osprey Medical announced a collaboration with GE Healthcare on Osprey’s Be Kind to Kidneys campa
Siemens Healthineers Showcases New In Vivo and In Vitro Cardiovascular Solutions at TCT 2018
News | Ultrasound Imaging | September 21, 2018
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers...
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cardiac Imaging | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
LVivo EF Cardiac Tool Now Available for GE Vscan Extend Handheld Mobile Ultrasound
Technology | Cardiovascular Ultrasound | September 19, 2018
DiA Imaging Analysis Ltd. (DiA), a provider of artificial intelligence (AI)-powered ultrasound analysis tools,...
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co